These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 30682030

  • 1. Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea.
    Yun JW, Choi MJ, Shin GS, Lim JO, Noh JY, Kim YK, Song JY, Kim WJ, Choi SE, Cheong HJ.
    PLoS One; 2019; 14(1):e0209643. PubMed ID: 30682030
    [Abstract] [Full Text] [Related]

  • 2. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
    Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E.
    Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC, Tan EC, Su JJ.
    Hum Vaccin Immunother; 2017 Jan 02; 13(1):81-89. PubMed ID: 27624648
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
    Jiang M, Li P, Wang W, Zhao M, Atif N, Zhu S, Fang Y.
    Vaccine; 2020 Jan 29; 38(5):1057-1064. PubMed ID: 31787414
    [Abstract] [Full Text] [Related]

  • 5. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK, Song JY, Jang H, Kim TH, Koo H, Varghese L, Han E.
    Pharmacoeconomics; 2018 Dec 29; 36(12):1475-1490. PubMed ID: 30251078
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G, Gregg M, Poulsen Nautrup B.
    J Med Econ; 2015 Dec 29; 18(9):746-61. PubMed ID: 25903831
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.
    You JH, Ming WK, Chan PK.
    Hum Vaccin Immunother; 2015 Dec 29; 11(3):564-71. PubMed ID: 25714506
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza vaccine for older adults in Argentina.
    Nguyen VH, Vizzotti C, Uruena A, Giglio N, Magneres C, Richmond H.
    Vaccine; 2020 Apr 29; 38(20):3682-3689. PubMed ID: 32249017
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
    Thommes EW, Ismaila A, Chit A, Meier G, Bauch CT.
    BMC Infect Dis; 2015 Oct 27; 15():465. PubMed ID: 26503131
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
    García A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J, Morano Larragueta R.
    Hum Vaccin Immunother; 2016 Sep 27; 12(9):2269-77. PubMed ID: 27184622
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.
    You JH, Ming WK, Chan PK.
    BMC Infect Dis; 2014 Nov 25; 14():618. PubMed ID: 25420713
    [Abstract] [Full Text] [Related]

  • 12. Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence.
    Loperto I, Simonetti A, Nardone A, Triassi M.
    Hum Vaccin Immunother; 2019 Nov 25; 15(5):1035-1047. PubMed ID: 30735465
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.
    Capri S, Barbieri M, de Waure C, Boccalini S, Panatto D.
    Hum Vaccin Immunother; 2018 Jun 03; 14(6):1331-1341. PubMed ID: 29425079
    [Abstract] [Full Text] [Related]

  • 14. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
    Yan H, Yang J, Chen ZY, Gong H, Zhong GJ, Yu HJ.
    Zhonghua Yi Xue Za Zhi; 2021 Aug 10; 101(30):2405-2412. PubMed ID: 34404135
    [Abstract] [Full Text] [Related]

  • 15. Adjuvanted influenza vaccine for the Italian elderly in the 2018/19 season: an updated health technology assessment.
    de Waure C, Boccalini S, Bonanni P, Amicizia D, Poscia A, Bechini A, Barbieri M, Capri S, Specchia ML, Di Pietro ML, Arata L, Cacciatore P, Panatto D, Gasparini R.
    Eur J Public Health; 2019 Oct 01; 29(5):900-905. PubMed ID: 30929026
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine for older adults in South Korea.
    Song Y, Shim E.
    Hum Vaccin Immunother; 2024 Dec 31; 20(1):2348124. PubMed ID: 38714332
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales.
    Mattock R, Gibbons I, Moss J, Mealing S, Largeron N, Carroll S, Alvarez FP.
    J Med Econ; 2021 Dec 31; 24(1):1261-1271. PubMed ID: 34726129
    [Abstract] [Full Text] [Related]

  • 18. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T, Forstén A, Arora A, Tsai T, Clemens R.
    Hum Vaccin Immunother; 2015 Dec 31; 11(8):2102-12. PubMed ID: 26091244
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
    de Boer PT, Crépey P, Pitman RJ, Macabeo B, Chit A, Postma MJ.
    Value Health; 2016 Dec 31; 19(8):964-975. PubMed ID: 27987647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.